Introducing LiquidHALLMARK®

A Swift, Simple and Sensitive Blood Test for Personalized Cancer Care
LiquidHALLMARK is an ultrasensitive next-generation sequencing assay for genomic profiling of a patient’s unique cancer. Requiring only a simple blood sample, LiquidHALLMARK is a broad biomarker panel that is quicker and less invasive compared to tissue biopsies.
LiquidHALLMARK is a comprehensive, amplicon-based NGS assay for ultrasensitive biomarker detection.
Powered by AmpliMARK, a proprietary amplicon-based sequencing technology, LiquidHALLMARK examines plasma circulating tumor DNA (ctDNA) mutations in 80 genes, including fusions in 10 genes. AmpliMARK is designed to be uniquely sensitive, providing >99% sensitivity at a detection limit of 0.1% Mutant Allele Frequency (MAF). The assay targets single nucleotide variants (including cis-trans), insertions and deletions, copy number variations (CNVs), microsatellite instability (MSI), fusions, and viruses.
LiquidHALLMARK targets have been identified in the following 15 cancers.
LiquidHALLMARK makes genomic profiling easier than ever before.
SWIFT

7-day Turnaround
SIMPLE

1 Blood Draw
SENSITIVE

0.1% Limit of Detection of MAF
Limit of Detection MAF | Sensitivity | Specificity | |
Single Nucleotide Variants (SNVs) | 0.1 % | > 99 % | > 99 % |
Insertions/ Deletions (Indels) | 0.1 % | > 95 % | > 99 % |
Fusions | 0.5 % | > 90 % | > 99 % |